Analysis of Chronic Disease Direct Cost at Public Primary Health Cares in Indonesia
Penulis/Author
Prof. Dr. Susi Ari Kristina, S.Farm., M.Kes., Apt. (2); Prof. dr. Ali Ghufron Mukti, M.Sc., Ph.D. (3); Prof. Dr. Satibi, S.Si., M.Si. Apt. (4)
Tanggal/Date
2021
Kata Kunci/Keyword
Abstrak/Abstract
Objectives: This study aims to analyze the of drug costs for patients with chronic diseases in the capitation system in public primary health cares (Public PHCs).
Materials and Methods: This research is a quantitative study with an observational cross-sectional approach at 16 Public PHCs. Data collection used the retrospective method. The total sample was 293 outpatients in 2016.
Results: The results showed that 63% of patients are female. The most patients are aged between 56-65 years (37%). The average drug cost for patients receiving more than 3 types of drugs is IDR 7,726. The biggest drug cost is patients with DM type 2 with which the average cost is IDR 7.400. And the metformin treatment is 17 (6%) patients with the cost IDR 4,500,-. Chi-square analysis shows that the quantity of drug items, type of disease and prescriptions there are have significant effect on drug cost (p-value <0.05). However, gender and age group there are no significant effect on drug cost (p-value >0.05). Drug prescriptions are an important component in managing chronic diseases patients. Prescribing costs provide important information in the sustainability of the management of chronic disease programs.
Conclusion: This study recommends that the prolanis policy in public PHCs is focused on the elderly age group patients and female group.
Rumpun Ilmu
Farmasi Umum dan Apoteker
Bahasa Asli/Original Language
English
Level
Internasional
Status
Dokumen Karya
No
Judul
Tipe Dokumen
Aksi
1
54131-Article Text-165880-1-10-20210629.pdf
[PAK] Full Dokumen
2
Analysis of Chronic Disease Direct Cost at Public Primary Health Cares in Indonesia.pdf
